Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX.
Protagonist Therapeutics Inc (PTGX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 6,196,006 | $411,600,679 | +1% | 1.68% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,560,916 | $170,121,650 | -21% | 6.9% |
| 3. | Deep Track Capital David Kroin | 1,715,691 | $113,973,353 | -48% | 3.18% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,438,247 | $95,542,748 | +52% | 0.45% |
| 5. | Driehaus Capital Richard Driehaus | 1,139,854 | $75,720,501 | +51% | 0.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.70 | 12,000 | $80,400.00 | 15,310 | 2020-03-12 | Filing | |
| $5.70 | 8,000 | $45,620.00 | 8,000 | 2019-12-03 | Filing | |
| $5.13 | 30,000 | $153,900.00 | 49,500 | 2019-12-03 | Filing | |
| $5.09 | 562 | $2,860.58 | 1,175 | 2019-12-03 | Filing | |
| $5.10 | 613 | $3,126.30 | 613 | 2019-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $84.77 | 2,712 | $229,896.24 | 81,180 | 2025-11-17 | Filing | |
| $87.81 | 8,000 | $702,480.00 | 5,130 | 2025-10-10 | Filing | |
| $69.25 | 4,000 | $277,000.00 | 13,130 | 2025-10-10 | Filing | |
| $64.25 | 4,000 | $257,000.00 | 5,130 | 2025-09-22 | Filing | |
| $59.25 | 4,000 | $237,000.00 | 9,130 | 2025-08-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,404,232 | $624,723,149 | 0.01% | |
| 2. | 5,756,277 | $382,389,481 | 4.71% | |
| 3. | 4,257,229 | $282,807,724 | 0% | |
| 4. | 3,165,795 | $210,303,762 | 0.01% | |
| 5. | 2,449,183 | $162,699,227 | 32.3% |
News See All
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now.
11 Best Mid Cap Growth Stocks To Invest In Now
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Top 10 Trending Stocks as AI Hype Fades
The US stock market took a major hit recently due to tariff-related uncertainties and a broader concern about AI stock valuations.